4-Fluoro Chalcone

4-Fluoro Chalcone

SCHEMBL657888

O=C(C=Cc1ccc(F)cc1)c1ccccc1

nearest known ligand 0.82

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNFRSF1A P19438 2/20 0.82
MAOB P27338 7/20 0.75
MAPT P10636 4/20 0.75
CYP1B1 Q16678 3/20 0.75
LMNA P02545 3/20 0.75
BCHE P06276 3/20 0.75
PLIN1 O60240 1/20 0.75
ACHE P22303 1/20 0.75
RECQL P46063 1/20 0.75
PLIN5 Q00G26 1/20 0.75
ABHD5 Q8WTS1 1/20 0.75
CYP3A4 P08684 4/20 0.71
NFKB1 P19838 2/20 0.71
NFKB2 Q00653 2/20 0.71
RELA Q04206 2/20 0.71
HSPD1 P10809 2/20 0.71
HSPE1 P61604 2/20 0.71
KMT2A Q03164 2/20 0.71
PKM P14618 1/20 0.71
RAB9A P51151 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
4-Fluoro Chalcone SCHEMBL657887 1.00 TNFRSF1A (0.82) TNFRSF1AMAOBMAPTCYP1B1LMNA
4-Fluoro Chalcone SCHEMBL10363601 1.00 TNFRSF1A (0.82) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL6586583 0.93 TNFRSF1A (0.82) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL11797296 0.93 TNFRSF1A (0.82) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL6593521 0.93 TNFRSF1A (0.82) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL5593308 0.90 TNFRSF1A (1.00) TNFRSF1AMAOBMAPTCYP1B1CYP3A4
SCHEMBL7196521 0.90 TNFRSF1A (1.00) TNFRSF1AMAOBMAPTCYP1B1CYP3A4
SCHEMBL8431772 0.90 CYP1B1 (0.91) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL9915665 0.90 CYP1B1 (0.91) TNFRSF1AMAOBMAPTCYP1B1LMNA
SCHEMBL25221701 0.87 TNFRSF1A (0.86) TNFRSF1AMAOBMAPTCYP1B1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504491-A Efficient preparation method and application of optically pure beta-cyano ketone 哈尔滨理工大学 2025-02-25 CN claimed
CN-117384199-A Preparation of novel organic aluminum hydrogen compound and preparation method of unsaturated alcohol compound catalyzed by novel organic aluminum hydrogen compound 北京理工大学 2024-01-12 CN claimed
EP-0926951-B1 TREATING PULMONARY DISEASES MEDIATED BY POLYUNSATURATED LIPID METABOLITES AND ASSAYS FOR EPOXIDE HYDROLASE INHIBITORS UNIV CALIFORNIA (US) 2004-04-21 EP claimed
EP-0485822-B1 Process for preparing high molecular weight polyolefines HOECHST AG (DE) 1996-07-03 EP claimed
EP-0485822-A2 Process for preparing high molecular weight polyolefines HOECHST AKTIENGESELLSCHAFT (DE) 1992-05-20 EP claimed
EP-4567018-A1 METHOD FOR PRODUCING FLUORINATED ORGANIC COMPOUND DAIKIN INDUSTRIES, LTD. (JP) 2025-06-11 EP disclosed
EP-4531824-A1 CHALCONE DERIVATIVES, MODULATOR OF FIBROBLASTS, FOR USE IN THE TREATMENT OF STROMA-RICH TUMORS Universiteit Gent (BE) 2025-04-09 EP disclosed
CN-119630628-A Process for producing fluorinated organic compound 大金工业株式会社 2025-03-14 CN disclosed
CN-119504491-A Efficient preparation method and application of optically pure beta-cyano ketone 哈尔滨理工大学 2025-02-25 CN disclosed
CN-119451668-A Chalcone derivatives and modulators of fibroblasts for the treatment of stromal rich tumors 根特大学 2025-02-14 CN disclosed
US-20250051299-A1 PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE DAIKIN INDUSTRIES, LTD. (JP) 2025-02-13 US disclosed
US-12162854-B2 Production method for fluoromethyl derivative DAIKIN INDUSTRIES, LTD. (JP) 2024-12-10 US disclosed
EP-0444533-A2 Quinoline and pyridine anchors for HMG-CoA reductase inhibitors E.R. SQUIBB & SONS, INC. (US) 1991-09-04 EP disclosed
WO-1991007382-A1 SUBSTITUTED SEMICARBAZONE ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-05-30 WO disclosed
WO-1990007495-A1 SUBSTITUTED SEMICARBAZONE ARTHROPODICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-07-12 WO disclosed
EP-0377304-A2 Substituted semicarbazone arthropodicides E.I. DU PONT DE NEMOURS AND COMPANY (US) 1990-07-11 EP disclosed
US-4910303-A Cataltyic reaction using N-alkylbis(2-hydroxyalkyl)amine TEXACO CHEMICAL COMPANY (US) 1990-03-20 US disclosed
EP-0356788-A2 Quinoline and pyridine anchors for HMG-CoA reductase inhibitors E.R. SQUIBB & SONS, INC. (US) 1990-03-07 EP disclosed
US-4898868-A ANTICHOLESTEROL AGENTS; LACTONE OR FREE ACID FORM HOECHST AKTIENGESELLSCHAFT (DE) 1990-02-06 US disclosed
US-4439418-A UNSATURATED ARYL KETONE HENKEL KGAA (DE) 1984-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162854-B2 Production method for fluoromethyl derivative AFF1, AFF2, ROS1 TNFRSF1A 4784/4885MAOB 20/4885MAPT 3085/4885
US-20250051299-A1 PRODUCTION METHOD FOR FLUOROMETHYL DERIVATIVE AFF1, AFF2, ROS1 TNFRSF1A 4784/4885MAOB 20/4885MAPT 3085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.